journal
MENU ▼
Read by QxMD icon Read
search

Prostate Cancer and Prostatic Diseases

journal
https://www.readbyqxmd.com/read/28071673/prognostic-value-of-the-new-grade-groups-in-prostate-cancer-a-multi-institutional-european-validation-study
#1
R Mathieu, M Moschini, B Beyer, K M Gust, T Seisen, A Briganti, P Karakiewicz, C Seitz, L Salomon, A de la Taille, M Rouprêt, M Graefen, S F Shariat
BACKGROUND: We aimed to assess the prognostic relevance of the new Grade Groups in Prostate Cancer (PCa) within a large cohort of European men treated with radical prostatectomy (RP). METHODS: Data from 27 122 patients treated with RP at seven European centers were analyzed. We investigated the prognostic performance of the new Grade Groups (based on Gleason score 3+3, 3+4, 4+3, 8 and 9-10) on biopsy and RP specimen, adjusted for established clinical and pathological characteristics...
January 10, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28071672/metformin-and-the-risk-of-prostate-cancer-across-racial-ethnic-groups-a-population-based-cohort-study
#2
C B Chen, D T Eurich, S R Majumdar, J A Johnson
BACKGROUND: Men with diabetes may have a lower risk of prostate cancer than men without diabetes which may be altered by metformin use or race/ethnicity. METHODS: Using administrative databases, from 1994 to 2012, adult (age⩾50 years) men with diabetes were identified. Metformin exposure was defined as a time-dependent variable, stratified first into any use, and into tertiles of cumulative dose. Surname algorithms identified individuals as Chinese or non-Chinese...
January 10, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28045115/skeletal-related-events-significantly-impact-health-related-quality-of-life-in-metastatic-castration-resistant-prostate-cancer-data-from-prevail-and-affirm-trials
#3
F Saad, C Ivanescu, D Phung, Y Loriot, S Abhyankar, T M Beer, B Tombal, S Holmstrom
BACKGROUND: We investigated the impact of skeletal-related events (SREs) on health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) in phase III trials of enzalutamide versus placebo. METHODS: Patients with mCRPC experiencing at least one SRE during AFFIRM and PREVAIL were assessed for trajectory-adjusted mean change in HRQoL by first SRE using Functional Assessment of Cancer Therapy-Prostate (FACT-P; AFFIRM, three domains, and PREVAIL, nine domains) and EQ-5D (PREVAIL) instruments...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28045114/treatment-of-m1a-m1b-prostate-cancer-with-or-without-radical-prostatectomy-at-diagnosis
#4
M Moschini, A Morlacco, E Kwon, L J Rangel, R J Karnes
BACKGROUND: The aim of the study was to evaluate survival and perioperative outcomes of metastatic prostate cancer (mPCa) patients treated with surgery or androgen deprivation treatment (ADT) only. METHODS: We retrospectively selected 47 metastatic PCa patients treated at a single center (Mayo Clinic, Rochester, MN) by two urologists (RJK and EK) between 2007 and 2014. Overall, 31 (66%) underwent radical prostatectomy (RP) with or without adjuvant therapies and 16 (34%) underwent ADT only...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28045113/unscreened-older-men-diagnosed-with-prostate-cancer-are-at-increased-risk-of-aggressive-disease
#5
J J Tosoian, R Alam, C Gergis, A Narang, N Radwan, S Robertson, T McNutt, A E Ross, D Y Song, T L DeWeese, P T Tran, P C Walsh
BACKGROUND: To evaluate the relationship between PSA testing history and high-risk disease among older men diagnosed with prostate cancer. METHODS: Records from 1993 to 2014 were reviewed for men who underwent radiotherapy for prostate cancer at age 75 years or older. Patients were classified into one of four groups based on PSA-testing history: (1) no PSA testing; (2) incomplete/ineffective PSA testing; (3) PSA testing; or (4) cannot be determined. Outcomes of interest were National Comprehensive Cancer Network (NCCN) risk group (that is, low, intermediate or high risk) and biopsy grade at diagnosis...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27958385/updated-postoperative-nomogram-incorporating-the-number-of-positive-lymph-nodes-to-predict-disease-recurrence-following-radical-prostatectomy
#6
D P Nguyen, M Kent, A Vilaseca, R B Corradi, N Fossati, D D Sjoberg, N Benfante, J A Eastham, P T Scardino, K A Touijer
BACKGROUND: A significant number of patients with minimal lymph node disease at radical prostatectomy (RP) and pelvic lymph node dissection (PLND) have better than expected long-term outcomes. We explored whether stratification by number of positive nodes enhances our institutional prediction model for biochemical recurrence after RP. METHODS: A total of 7789 patients underwent RP and pelvic lymph node dissection from 1995 to 2012 at a tertiary referral center. We compared two recurrence prediction models: one incorporated lymph node invasion and the other tracked the number of positive nodes...
December 13, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27922627/blood-based-and-urinary-prostate-cancer-biomarkers-a-review-and-comparison-of-novel-biomarkers-for-detection-and-treatment-decisions
#7
REVIEW
R J Hendriks, I M van Oort, J A Schalken
BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making...
December 6, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27897172/adaptation-and-external-validation-of-the-european-randomised-study-of-screening-for-prostate-cancer-risk-calculator-for-the-chinese-population
#8
P K Chiu, M J Roobol, D Nieboer, J Y Teoh, S K Yuen, S M Hou, M K Yiu, C F Ng
BACKGROUND: To adapt the well-performing European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator to the Chinese setting and perform an external validation. METHODS: The original ERSPC risk calculator 3 (RC3) for prostate cancer (PCa) and high-grade PCa (HGPCa) was applied to a development cohort of 3006 previously unscreened Hong Kong Chinese men with initial transrectal biopsies performed from 1997 to 2015, age 50-80 years, PSA 0.4-50 ng ml(-1) and prostate volume 10-150 ml...
November 29, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27845330/the-prognostic-role-of-tertiary-gleason-pattern-5-in-a-contemporary-grading-system-for-prostate-cancer
#9
W S Jang, C Y Yoon, M S Kim, D H Kang, Y J Kang, W S Jeong, M J Abalajon, W S Ham, Y D Choi
BACKGROUND: Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the prognostic role of TGP5 in the new classification. METHODS: We retrospectively reviewed the records of 1396 patients with localized GS 6-8 PC (pT2-3N0M0) who underwent radical prostatectomy at our institution between 2005 and 2014...
November 15, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27824043/duration-of-the-anti-androgen-in-men-undergoing-6-months-of-an-lhrh-agonist-and-radiation-therapy-for-unfavorable-risk-prostate-cancer-and-the-risk-of-death
#10
N N Sanford, M-H Chen, M Loffredo, A Renshaw, P W Kantoff, A V D'Amico
BACKGROUND: Whether adding a first-generation anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all-cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is unknown. METHODS: Between 1995 and 2001, 206 men with unfavorable-risk PC were enrolled in a randomized trial comparing radiation with or without 6 months of androgen-deprivation therapy (ADT)...
November 8, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27824042/the-role-of-salvage-extended-lymph-node-dissection-in-patients-with-rising-psa-and-pet-ct-scan-detected-nodal-recurrence-of-prostate-cancer
#11
D Porres, D Pfister, A Thissen, T H Kuru, V Zugor, R Buettner, R Knuechel, F A Verburg, A Heidenreich
BACKGROUND: Non-prostatic bed recurrence of prostate cancer (PCa) is usually treated with androgen deprivation therapy (ADT). We analyzed the impact of salvage extended lymph node dissection (sLND) on cancer control in patients with rising PSA and lymph node (LN) metastases. METHODS: Between 2009 and 2016 we performed sLND in 87 patients with biochemical recurrence (BCR) and positive LNs on (18)FEC and (68)Ga-PSMA positron emission tomography/X-ray computer tomography (PET/CT) after primary treatment (PT) of PCa...
November 8, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27801901/correlation-of-b7-h3-with-androgen-receptor-immune-pathways-and-poor-outcome-in-prostate-cancer-an-expression-based-analysis
#12
B Benzon, S G Zhao, M C Haffner, M Takhar, N Erho, K Yousefi, P Hurley, J L Bishop, J Tosoian, K Ghabili, M Alshalalfa, S Glavaris, B W Simons, P Tran, E Davicioni, R J Karnes, K Boudadi, E S Antonarakis, E M Schaeffer, C G Drake, F Feng, A E Ross
BACKGROUND: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules, has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism of action remain unclear. B7-H3 protein expression correlates with prostate cancer outcomes, and humanized monoclonal antibodies (that is, enoblituzumab) are currently being investigated for therapeutic use. Here we used genomic expression data to examine the relationship between B7-H3 mRNA expression and prostate cancer...
November 1, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27801900/active-surveillance-for-intermediate-risk-prostate-cancer
#13
REVIEW
M A Dall'Era, L Klotz
BACKGROUND: Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with intermediate-risk featuresMethods:PubMed was queried for all relevant original publications describing outcomes for men with prostate cancer managed with AS. Outcomes for patients with intermediate-risk features as defined by the primary investigators were studied when available and compared with similar risk men undergoing immediate treatment...
November 1, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27779203/socs1-inhibits-migration-and-invasion-of-prostate-cancer-cells-attenuates-tumor-growth-and-modulates-the-tumor-stroma
#14
A Villalobos-Hernandez, D Bobbala, R Kandhi, M G M Khan, M Mayhue, C M Dubois, G Ferbeyre, C Saucier, S Ramanathan, S Ilangumaran
BACKGROUND: The suppressor of cytokine signaling 1 (SOCS1) gene is repressed in prostate cancer (PCa) by epigenetic silencing and microRNA miR30d. Increased expression of the SOCS1-targeting miR30d correlates with higher biochemical recurrence, suggesting a tumor suppressor role of SOCS1 in PCa, but the underlying mechanisms are unclear. We have shown that SOCS1 inhibits MET receptor kinase signaling, a key oncogenic pathway in cancer progression. Here we evaluated the role of SOCS1 in attenuating MET signaling in PCa cells and tumor growth in vivo...
October 25, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27779202/the-impact-of-local-treatment-of-the-primary-tumor-site-in-node-positive-and-metastatic-prostate-cancer-patients
#15
M Moschini, F Soria, A Briganti, S F Shariat
BACKGROUND: Surgical treatment of the primary tumor in patients with metastatic prostate cancer (mPCa) is gaining traction. We discuss the biological rational and the existing literature on this approach. METHODS: We reviewed the literature regarding surgical management of advanced and mPCa disease. RESULTS: Surgical removal of the primary tumor despite metastases is becoming a standard in an increasing number of malignancies. Basic science data support the use of surgical removal of the prostate in metastatic PCa...
October 25, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27618950/the-very-high-risk-prostate-cancer-a-contemporary-update
#16
R Mano, J Eastham, O Yossepowitch
BACKGROUND: Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment alternatives in very-high-risk prostate cancer. METHODS: We searched the MEDLINE database for all clinical trials or practice guidelines published in English between 2000 and 2016, with the following search terms: 'prostatic neoplasms' (MeSH Terms) AND ('high risk' (keyword) OR 'locally advanced' (keyword) OR 'node positive' (keyword))...
September 13, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27595915/a-meta-analysis-of-cardiovascular-events-in-intermittent-androgen-deprivation-therapy-versus-continuous-androgen-deprivation-therapy-for-prostate-cancer-patients
#17
REVIEW
C Jin, Y Fan, Y Meng, C Shen, Y Wang, S Hu, C Cui, T Xu, W Yu, J Jin
BACKGROUND: Androgen-deprivation therapy (ADT) is the standard treatment for advanced and recurrent prostate cancer but it has been shown to cause adverse effects on the cardiovascular system. Intermittent androgen deprivation has been studied as an alternative therapy. To conduct a meta-analysis comparing the incidence of cardiovascular events in patients with prostate cancer receiving intermittent (IADT) versus continuous ADT (CADT). METHODS: We searched Cochrane CENTRAL, PubMed/Medline, Embase, Web of Science, The National Cancer Institute Clinical Trials and The Clinical Trials Register of Trials Central, and Google Scholar from inception of each database through February 2016...
December 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27574020/decipher-correlation-patterns-post-prostatectomy-initial-experience-from-2%C3%A2-342-prospective-patients
#18
R B Den, M Santiago-Jimenez, J Alter, M Schliekelman, J R Wagner, J F Renzulli Ii, D I Lee, C G Brito, K Monahan, B Gburek, N Kella, G Vallabhan, F Abdollah, E J Trabulsi, C D Lallas, L G Gomella, T L Woodlief, Z Haddad, L L C Lam, S Deheshi, Q Wang, V Choeurng, M du Plessis, J Jordan, B Parks, H Shin, C Buerki, K Yousefi, E Davicioni, V R Patel, N L Shah
BACKGROUND: Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we examined the correlation patterns of Decipher assay to understand the relationship between the Decipher and patient tumor characteristics. METHODS: De-identified Decipher test results (including Decipher risk scores and clinicopathologic data) from 2 342 consecutive radical prostatectomy (RP) patients tested between January and September 2015 were analyzed...
December 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27502739/tumor-features-and-survival-after-radical-prostatectomy-among-antidiabetic-drug-users
#19
R M Joentausta, P M Kujala, T Visakorpi, T L J Tammela, T J Murtola
BACKGROUND: To evaluate the association between use of metformin and other antidiabetic drugs with tumor characteristics and survival in surgically managed prostate cancer (PCa) patients. METHODS: The study population included 1314 men who underwent radical prostatectomy at the Tampere University Hospital during 1995-2009. Causes of deaths were collected from the Finnish Cancer Registry. Individual-level data on medication use during 1995-2009 was obtained from national prescription database...
December 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27502738/morbidity-and-mortality-after-surgery-for-lower-urinary-tract-symptoms-a-study-of-95%C3%A2-577-cases-from-a-nationwide-german-health-insurance-database
#20
C Gilfrich, H Leicht, C Fahlenbrach, E Jeschke, G Popken, J U Stolzenburg, L Weißbach, C Zastrow, C Günster
BACKGROUND: Little real-world data is available on the comparison of different methods in surgery for lower urinary tract symptoms due to benign prostatic obstruction in terms of complications. The objective was to evaluate the proportions of TURP, open prostatectomy (OP) and laser-based surgical approaches over time and to analyse the effect of approach on complication rates. METHODS: Using data of the German local healthcare funds (Allgemeine Ortskrankenkassen (AOK)), we identified 95 577 cases with a primary diagnosis of hyperplasia of prostate who received TURP, laser vaporisation (LVP), laser enucleation (LEP) of the prostate or OP between 2008 and 2013...
August 9, 2016: Prostate Cancer and Prostatic Diseases
journal
journal
33118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"